Wall Street brokerages expect that OraSure Technologies (NASDAQ:OSUR) will announce sales of $40.55 million for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for OraSure Technologies’ earnings. The lowest sales estimate is $40.50 million and the highest is $40.59 million. OraSure Technologies posted sales of $32.55 million during the same quarter last year, which suggests a positive year-over-year growth rate of 24.6%. The firm is scheduled to announce its next earnings results on Wednesday, May 2nd.
On average, analysts expect that OraSure Technologies will report full-year sales of $40.55 million for the current financial year, with estimates ranging from $179.22 million to $182.00 million. For the next fiscal year, analysts expect that the company will post sales of $198.03 million per share, with estimates ranging from $195.06 million to $201.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover OraSure Technologies.
OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings data on Wednesday, February 7th. The medical instruments supplier reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.01. The firm had revenue of $52.00 million during the quarter, compared to analysts’ expectations of $50.20 million. OraSure Technologies had a return on equity of 13.09% and a net margin of 18.52%. OraSure Technologies’s revenue was up 46.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.13 earnings per share.
Shares of OSUR stock opened at $16.72 on Monday. The firm has a market cap of $1,028.18, a P/E ratio of 32.78, a PEG ratio of 4.95 and a beta of 1.65. OraSure Technologies has a 1 year low of $12.02 and a 1 year high of $23.01.
In other news, EVP Brian Smith sold 20,000 shares of the business’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $17.97, for a total value of $359,400.00. Following the completion of the transaction, the executive vice president now directly owns 28,075 shares of the company’s stock, valued at $504,507.75. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Stephen S. Phd Tang sold 23,333 shares of the business’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $17.97, for a total value of $419,294.01. Following the completion of the transaction, the director now directly owns 59,749 shares of the company’s stock, valued at $1,073,689.53. The disclosure for this sale can be found here. Insiders own 6.40% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in OSUR. Elkfork Partners LLC acquired a new position in OraSure Technologies in the fourth quarter valued at $143,000. Oppenheimer Asset Management Inc. acquired a new position in OraSure Technologies in the third quarter valued at $186,000. Shikiar Asset Management Inc. acquired a new position in OraSure Technologies in the fourth quarter valued at $207,000. AMP Capital Investors Ltd acquired a new position in OraSure Technologies in the fourth quarter valued at $294,000. Finally, Quadrant Private Wealth Management LLC acquired a new position in OraSure Technologies in the fourth quarter valued at $300,000. 93.67% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This story was first reported by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/3342275/40-55-million-in-sales-expected-for-orasure-technologies-osur-this-quarter.html.
OraSure Technologies Company Profile
OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.